RxDoctor Payments Data

Todd Odom, MD

Colon & Rectal Surgery · Plano, TXNPI 1801860952

Payments from drug & device makers

$431in general payments, 2019–2025

Across 21 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$83
  • Braintree Laboratories, Inc.$76
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$67
  • Pfizer$40
  • AbbVie$37
  • TELA Bio, Inc.$26
  • plus $103 from 6 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$431 in reported general payments places this provider in the 10th percentile of 200 colon & rectal surgery providers in Texas.

See all colon & rectal surgery providers in Texas

Medicare billing

Part B allowed, 2024
$188,014
Medicare patients
762
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab12$161,462
Budesonide ErBudesonide15$16,700
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates233$15,280
SutabSod Sulf/Pot Chloride/Mag Sulf89$14,370
LinzessLinaclotide17$12,095
Mesalamine62$10,725
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag23$2,792
ClenpiqSod Picosulf/Mag Ox/Citric Ac14$2,431
Mercaptopurine17$2,271
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl90$1,260
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine37$1,115
Ondansetron Hcl473$871
Gabapentin88$837
Hydrocortisone43$683
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl42$620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Linzess$37$173,55629 claims
Braintree Laboratories, Inc.Sutab, Suflave$76$17,162112 claims
Ferring Pharmaceuticals Inc.Clenpiq$12$2,43114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 200 colon & rectal surgery providers in Texas.

Other colon & rectal surgery in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →